Overview

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Open-label, multicenter study in adults with Primary Biliary Cirrhosis (PBC) designed to evaluate the long-term safety and tolerability of daily dosing with LUM001.
Phase:
Phase 2
Details
Lead Sponsor:
Mirum Pharmaceuticals, Inc.
Shire